Example of successful therapy whith nilotinib at resistant to interferon and glivec patient with chronic phase of Ph-positive chronic myeloid leucosis

Example of successful therapy whith nilotinib at resistant to interferon and glivec patient with chronic phase of Ph-positive chronic myeloid leucosis

.

Bibliographic Details
Main Authors:	G. A. Gusarova, N. A. Afanasiyeva
Format:	Article
Language:	English
Published:	Siberian State Medical University (Tomsk) 2008-12-01
Series:	Бюллетень сибирской медицины
Online Access:	https://bulletin.ssmu.ru/jour/article/view/3929

Similar Items

The case of successful therapy with Nilotinib in patients with Ph-positive chronic myelogenous leukemia of chronic phase resistant to Interferon and Gleevec
by: N. A. Afanasyeva, et al.
Published: (2022-11-01)

S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
by: Andreas Hochhaus, et al.
Published: (2023-08-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

EFFICACY OF NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
by: Sajid Ali, et al.
Published: (2019-12-01)

MICROBIOCENOSIS IN CHILDREN WHITH CHRONIC RECURRENT PYELONEPHRITIS.
by: О. Lavrenchuk
Published: (2014-04-01)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec&reg;, Gleevec&trade;)
by: Martin Henkes, et al.
Published: (2008-03-01)

Development and targeted use of nilotinib in chronic myeloid leukemia
by: Carmen Fava, et al.
Published: (2008-11-01)

Nilotinib in Chronic Myeloid Leukemia: a comprehensive approach
by: Mario Annunziata
Published: (2015-10-01)

Thyroid dysfunction in chronic myeloid leukemia patients on nilotinib
by: Khaleed J Khaleel, et al.
Published: (2018-01-01)

Metformin enhances the cytotoxic effect of nilotinib and overcomes nilotinib resistance in chronic myeloid leukemia cells
by: Yoo Jin Na, et al.
Published: (2021-03-01)

Effects of nilotinib on platelet function in patients with chronic myeloid leukemia in chronic phase
by: Alauldeen Mudhafar Zubair Alqasim, et al.
Published: (2019-01-01)

First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluation
by: Piccaluga PP, et al.
Published: (2012-11-01)

Nilotinib-Induced Acute Pancreatitis in a Patient with Chronic Myeloid Leukemia
by: Vihang Patel, et al.
Published: (2017-05-01)

Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib
by: Shunsuke Maruta, et al.
Published: (2021-08-01)

Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
by: Miguel Carracedo, PhD, et al.
Published: (2020-03-01)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
by: Rafiyath Shamudheen, et al.
Published: (2010-11-01)

Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
by: Husam N. Al-Dubai, et al.
Published: (2020-06-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Efficacy and safety of tyrosine kinase inhibitors (dasatinib, nilotinib) in the treatment of chronic phase chronic myeloid leukemia
by: E. G. Lomaia, et al.
Published: (2014-07-01)

Successful treatment with nilotinib after bosutinib-induced pulmonary arterial hypertension recurrence following dasatinib in chronic myeloid leukemia in chronic phase
by: Ibuki Takatsuka, et al.
Published: (2022-01-01)

Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia
by: N. A. Avxentyev, et al.
Published: (2018-08-01)

Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response
by: Yuji Okamoto, et al.
Published: (2022-10-01)

Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
by: Min Jeong Kim
Published: (2021-12-01)

Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
by: Ronan Swords, et al.
Published: (2009-03-01)

A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTKorea
by: Junghoon Shin, et al.
Published: (2018-05-01)

Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia
by: Mert Tokatlı, et al.
Published: (2024-03-01)

Gonadotoxic Effects of Nilotinib in Chronic Myeloid Leukemia Treatment Dose in a Mouse Model
by: Güldane Seval, et al.
Published: (2017-05-01)

Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
by: David Sanford, et al.
Published: (2014-06-01)

Nilotinib therapy in an imatinib intolerant chronic myeloid leukemia patient with pulmonary severe hypertension
by: Mario Annunziata
Published: (2015-10-01)

Safety and Efficacy of Elective Switch from Nilotinib to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
by: Ali Ibrahim, et al.
Published: (2022-05-01)

Chronic myeloid leukemia: successful therapy with nilotinib in a young patient with high Sokal risk and in sub-optimal response with imatinib
by: Fausto Palmieri
Published: (2015-10-01)

S156: INTERNATIONAL, PROSPECTIVE STUDY COMPARING NILOTINIB VERSUS IMATINIB WITH EARLY SWITCH TO NILOTINIB TO OBTAIN SUSTAINED TREATMENT-FREE REMISSION IN PATIENTS WITH WITH CHRONIC MYELOID LEUKEMIA
by: F. Pane, et al.
Published: (2022-06-01)

Simvastatin enhances the efficacy of Bcr-Abl tyrosine kinase inhibitor nilotinib in chronic myeloid leukemia.
by: Koh, Yanqing.
Published: (2011)

Imatinib resistance was reversed by nilotinib in the acute transformation of chronic myeloid leukemia: A case report
by: Meng Xiao, et al.
Published: (2017-12-01)

Nilotinib for the frontline treatment of chronic myeloid leukemia carrying the p230 transcript: dream or reality?
by: Maurizio eCapuozzo, et al.
Published: (2014-02-01)

Modern therapy and prognostic factors at chronic lymphoid leucosis. Review of literature and own datas
by: Ye. A. Stadnik, et al.
Published: (2008-12-01)

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia
by: Harnicar S, et al.
Published: (2014-08-01)

Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34− and immature CD34+ cells
by: Marc G. Berger, et al.
Published: (2021-03-01)